- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT05214625
Questionnaire Study Concerning Artificial Intelligence
Questionnaire Study Concerning Artificial Intelligence and Its Application in (Gastrointestinal) Healthcare - Patients' and Physicians' Perspectives
Panoramica dello studio
Stato
Condizioni
Intervento / Trattamento
Descrizione dettagliata
In recent years, important developments have been made in the field of artificial intelligence (AI). These developments have led to the large-scale application of AI in our everyday lives and AI-research within healthcare. A potentially promising application of AI lies in imaging analysis. For example, within gastroenterology this means the detection and classification of colorectal polyps and Barrett's neoplasia, disease severity scoring of inflammatory bowel diseases, and differentiating pancreatic cancer from chronic pancreatitis.
Despite the investments in AI-research, there is a lack in knowledge concerning patients' and physicians' perspectives on AI in healthcare. This prospective questionnaire study investigates these perspectives, obtaining data from both gastroenterology (GI) patients and GI-physicians within the Netherlands. The questionnaires focus on the knowledge, experience, and opinion of AI, particularly concerning the implementation of AI in (gastroenterology) healthcare. Furthermore, the current (endoscopic) infrastructure within Dutch hospitals will be investigated for its readnessy for AI.
Tipo di studio
Iscrizione (Effettivo)
Contatti e Sedi
Luoghi di studio
-
-
Limburg
-
Maastricht, Limburg, Olanda, 6202AZ
- Maastricht University Medical Center
-
-
Noord-Brabant
-
Eindhoven, Noord-Brabant, Olanda, 5623 EJ
- Catharina Ziekenhuis Eindhoven
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Metodo di campionamento
Popolazione di studio
Gastroenterology patients who will have an outpatient appointment for an endoscopic procedure in the context of the national bowel cancer screening program, because of gastrointestinal symptoms, or because of follow-up of previously diagnosed bowel diseases, in one of two Dutch hospitals between April 2020 and September 2020.
Gastroenterologists and gastroenterology fellows working in Dutch hospitals.
Descrizione
Inclusion Criteria:
- Gastrointestinal (GI) patients with an outpatient appointment in the gastroenterology department for an endoscopic procedure in the context of the Dutch national screening program, because of gastrointestinal symptoms, or because of follow-up of previously diagnosed bowel diseases (in one of the two participating hospitals);
- Gastroenterologists working in Dutch hospitals;
- Gastroenterology fellows working in Dutch hospitals;
- Minimal age of 18 years old.
Exclusion Criteria:
- No appropriate understanding of the Dutch language;
- Not willing to sign informed consent;
- Objection to participate in medical scientific research, reported in the medical file.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
Coorti e interventi
Gruppo / Coorte |
Intervento / Trattamento |
|---|---|
|
Gastroenterology patients
Patient receiving an endoscopic procedure because of regular care will be considered eligible for inclusion. Patients receive an endoscopic procedure in the context of the Dutch national screening program, because of gastrointestinal symptoms, or because of follow-up of previously diagnosed bowel diseases. Patients will be asked to complete a questionnaire concerning AI. No intervention will be administered. |
Questionnaire concerning artificial intelligence and its implementation in healthcare.
GI patients and GI physicians will be provided with slightly different questionnaires.
|
|
Gastroenterology physicians
GI physicians (both gastroenterologists and gastroenterology fellows), participating in a yearly gastroenterology and hepatology training day, will be asked for their participation in this study. Physician will be asked to complete a questionnaire concerning AI. No intervention will be administered. |
Questionnaire concerning artificial intelligence and its implementation in healthcare.
GI patients and GI physicians will be provided with slightly different questionnaires.
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
The knowledge on AI investigated by means of a questionnaire
Lasso di tempo: 6 months
|
The knowledge on AI in healthcare among gastroenterology patients and physicians, investigated by means of a questionnaire.
|
6 months
|
|
The experience with AI investigated by means of a questionnaire
Lasso di tempo: 6 months
|
The experience with AI (in healthcare) among gastroenterology patients and physicians, investigated by means of a questionnaire.
|
6 months
|
|
The opinion on AI investigated by means of a questionnaire
Lasso di tempo: 6 months
|
The oninion on AI in healthcare among gastroenterology patients and physicians, investigated by means of a questionnaire.
|
6 months
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Willingness of physicians to use AI in (gastroenterology) healthcare
Lasso di tempo: 6 months
|
The willingness to apply AI in (gastroenterology) healthcare among gastroenterology physicians.
|
6 months
|
|
Willingness to apply AI in (gastroenterology) healthcare
Lasso di tempo: 6 months
|
The willingness of gastroenterology patients for their physicians to apply AI in (gastroenterology) healthcare.
|
6 months
|
|
Advantages and disadvantages of AI use in (gastroenterology) healthcare
Lasso di tempo: 6 months
|
Important advantages and disadvantages of AI use in (gastroenterology) healthcare among gastroenterology patients and physicians.
|
6 months
|
|
Potential domains within gastroenterology and hepatology for AI use
Lasso di tempo: 6 months
|
Potential domains within gastroenterology and hepatology for AI use indicated by GI physicians.
|
6 months
|
|
Mandatory infrastructure for AI use in healthcare
Lasso di tempo: 6 months
|
The availability of technical facilities and infrastructures within endoscopy to implement and apply AI in Dutch hospitals.
|
6 months
|
Collaboratori e investigatori
Collaboratori
Investigatori
- Investigatore principale: Ad Masclee, Prof Dr MD, Maastricht Universitair Medisch Centrum
Pubblicazioni e link utili
Pubblicazioni generali
- Le Berre C, Sandborn WJ, Aridhi S, Devignes MD, Fournier L, Smail-Tabbone M, Danese S, Peyrin-Biroulet L. Application of Artificial Intelligence to Gastroenterology and Hepatology. Gastroenterology. 2020 Jan;158(1):76-94.e2. doi: 10.1053/j.gastro.2019.08.058. Epub 2019 Oct 5.
- Shaban-Nejad A, Michalowski M, Buckeridge DL. Health intelligence: how artificial intelligence transforms population and personalized health. NPJ Digit Med. 2018 Oct 2;1:53. doi: 10.1038/s41746-018-0058-9. eCollection 2018.
- Labovitz DL, Shafner L, Reyes Gil M, Virmani D, Hanina A. Using Artificial Intelligence to Reduce the Risk of Nonadherence in Patients on Anticoagulation Therapy. Stroke. 2017 May;48(5):1416-1419. doi: 10.1161/STROKEAHA.116.016281. Epub 2017 Apr 6.
- Waymel Q, Badr S, Demondion X, Cotten A, Jacques T. Impact of the rise of artificial intelligence in radiology: What do radiologists think? Diagn Interv Imaging. 2019 Jun;100(6):327-336. doi: 10.1016/j.diii.2019.03.015. Epub 2019 May 6.
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Completamento primario (Effettivo)
Completamento dello studio (Effettivo)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- METC 2020-2281
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Descrizione del piano IPD
Periodo di condivisione IPD
Criteri di accesso alla condivisione IPD
Tipo di informazioni di supporto alla condivisione IPD
- STUDIO_PROTOCOLLO
- LINFA
- ICF
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .